Non-Rhabdomyosarcoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Non-Rhabdomyosarcoma – Drugs In Development, 2023’, provides an overview of the Non-Rhabdomyosarcoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Non-Rhabdomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Rhabdomyosarcoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non-Rhabdomyosarcoma
- The report reviews pipeline therapeutics for Non-Rhabdomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Rhabdomyosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Non-Rhabdomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Rhabdomyosarcoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Rhabdomyosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAadi Bioscience Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Agency for Science
Technology and Research
Akeso Inc
Amgen Inc
AntiCancer Inc
ANTUREC Pharmaceuticals GmbH
APIM Therapeutics AS
Ascentage Pharma Group International
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVM Biotechnology LLC
Bayer AG
BeiGene Ltd
BioAtla Inc
BioInvent International AB
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cebiotex SL
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Clinigen Ltd
CoBioRes NV
Concentra Biosciences LLC
CStone Pharmaceuticals Co Ltd
Curadev Pharma Pvt Ltd
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Eisai Co Ltd
Eli Lilly and Co
Eucure (Beijing) Biopharma Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Hutchison MediPharma Ltd
Immatics NV
Immutep Ltd
Incyte Corp
Innovent Biologics Inc
Intezyne Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Kronos Bio Inc
Lixte Biotechnology Holdings Inc
Lyell Immunopharma Inc
Lytix Biopharma AS
Mediolanum farmaceutici SpA
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Moleculin Biotech Inc
Nationwide Children's Hospital
Novartis AG
OncoResponse Inc
OrphAI Therapeutics Inc
Orum Therapeutics Inc
Osaka University
Paranta Biosciences Ltd
Perseus Proteomics Inc
Pfizer Inc
Pharma Mar SA
Philogen SpA
PTC Therapeutics Inc
Pyxis Oncology Inc
QBiotics Group Ltd
Salk Institute for Biological Studies
Sanofi
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
SOTIO Biotech AS
Syena
Syndivia SAS
Takeda Pharmaceutical Co Ltd
Tempest Therapeutics Inc
TRACON Pharmaceuticals Inc
United Immunity Co Ltd
University of South Australia
Veltion Therapeutics LLC
Wigen Biomedicine Technology (Shanghai) Co Ltd
Zhuhai Beihai Biotech Co Ltd